Longevity Technology

How near are we to technology that could allow humans to live much longer lives? Surprisingly close. Our goal is to unite innovators, researchers, insurers, policymakers, practitioners, and commentators to explore the emerging and rapidly expanding field of science and investment that will influence the future of our global population and economy: LONGEVITY.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#299064

United States

#108569

Health/Health

#2238

Traffic sources

Monthly visitors

Articles

Juvenescence acquires Ro5 to bolster AI drug discovery

2 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech powerhouse Juvenescence has expanded its AI-driven drug discovery capabilities through the acquisition of Ro5, a company specializing in AI and machine learning platforms for pharmaceutical research. The strategic move aims to accelerate the development of Juvenescence’s pipeline of therapeutics targeting age-related diseases, also strengthens its ongoing partnership with Abu Dhabi healthcare giant M42.
Risky business: Polygenic risk scores and the path to prevention

3 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Last month, British healthtech firm Genomics Ltd announced a collaboration with Danish pharmaceutical giant Novo Nordisk to identify individuals who are genetically predisposed to obesity by combining polygenic risk scores (PRS) with clinical factors. Polygenic risk scores estimate a person’s inherited risk for complex traits or diseases by aggregating the influence of thousands – or even millions – of common genetic variants, each with a small effect.
Insilico’s IPF drug demonstrated ‘clinically meaningful’ benefits

3 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity focused AI-powered drug developer Insilico Medicine has published the results of its Phase 2a idiopathic pulmonary fibrosis (IPF) clinical trial results in Nature Medicine. The trial studied the efficacy of Rentosertib, a novel TNIK inhibitor developed using the company’s generative AI platform, in the treatment of patients with IPF.
Magnitude Biosciences lands funding to accelerate longevity drug development

4 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp UK-based contract research organization Magnitude Biosciences, has secured more than £700,000 in combined investment and grant funding to advance its high-throughput drug discovery platform for in vivo testing using the transparent nematode (worm) model C elegans.
Prevention-focused unicorn Omada Health plots IPO

5 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Tech-enabled preventive healthcare company Omada Health aims to raise $158 million in an initial public offering that reportedly values the company at around $1.1 billion. Since 2012, Omada has evolved from a virtual diabetes and weight management provider into a comprehensive prevention platform, which is primarily focused on driving “behavior change” to improve the health of its members.
BioAge plots clinical trial of NLRP3 inhibitor this year

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech BioAge Labs has announced the completion of investigational new drug (IND)-enabling studies for BGE-102, the company’s novel small-molecule NLRP3 inhibitor, as it advances toward clinical development. BGE-102 is designed as an orally available, brain-penetrant compound with high potency, and it is being developed initially for the treatment of obesity.
Vivodyne lands $40m to replace animal testing in drug development

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp US biotech Vivodyne has secured $40 million in Series A funding led by Khosla Ventures for its mission to eliminate the need for animal testing drug development. The company leverages robotics and AI to grow and analyze thousands of fully functional human tissues, directly addressing the biological mismatch that underpins the staggering 95% failure rate in human clinical trials following successful animal tests.
Longevity 1.0 and the rise of the healthspan economy

1 week ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp The longevity sector, long defined by scientific breakthroughs, venture funding and cautious regulatory progress, is now experiencing a quiet but significant shift: an increasing embrace by the broader wellness industry. As consumer interest in aging well moves from fringe curiosity to mainstream ambition, the conversation is widening – and so are the platforms where it takes place.
Tally Health teams up with Pvolve and Cenegenics

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Consumer longevity biotech Tally Health has announced two new partnerships focused on advancing personalized approaches to managing aging. The strategic collaborations – with performance health company Cenegenics and functional fitness brand Pvolve – seek to integrate Tally’s epigenetic science with lifestyle-based wellness strategies to drive healthspan improvements.
Bryan Johnson joins Founders Longevity Forum London line-up

1 week ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp The Founders Longevity Forum returns to London on 10 June, once again bringing together a curated cohort of longevity investors, biotech entrepreneurs and translational scientists. The forum, co-hosted by Founders Forum Group and Longevity.Technology, will take place at OXO2 – a central, riverside venue – as part of London Tech Week.